Kuros Biosciences AG Company Description

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing.

The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG

Country	Switzerland
Founded	2016
Industry	Biological Products, Except Diagnostic Substances
Employees	122
CEO	Christopher Fair

Contact Details

Address: Wagistrasse 25 Schlieren, 8952 Switzerland
Phone	41 44 733 4747
Website	kurosbio.com

Stock Details

Ticker Symbol	YTSN
Exchange	Deutsche Börse Xetra
Fiscal Year	January - December
Reporting Currency	CHF
SIC Code	2836

Key Executives

Name	Position
Christopher Fair	Chief Executive Officer
Daniel Geiger	Chief Financial Officer
Sjoerd Musters	Chief Operating Officer